Microbial biomolecule-driven identification of next-gen GSK-3β inhibitors for brain disorders
- 19 December 2025
- journal article
- Published by Elsevier in Computational Biology and Chemistry
- Vol. 121, 108860
Abstract
No abstract availableKeywords
This publication has 91 references indexed in Scilit:
- In-silico DFT studies and molecular docking evaluation of benzimidazo methoxy quinoline-2-one ligand and its Co, Ni, Cu and Zn complexes as potential inhibitors of Bcl-2, Caspase-3, EGFR, mTOR, and PI3K, cancer-causing proteinsChemical Physics Impact, 2023
- Hallmarks of neurodegenerative diseasesCell, 2023
- β‐amino carbonyl derivatives: Synthesis, Molecular Docking, ADMET, Molecular Dynamic and Herbicidal studies.ChemistrySelect, 2022
- Molecular Docking and Antibacterial Studies of Pyranopyrazole Derivatives Synthesized Using [Pap-Glu@Chi] Biocatalyst Through a Greener ApproachArabian Journal for Science and Engineering, 2021
- The physiological roles of tau and Aβ: implications for Alzheimer’s disease pathology and therapeuticsActa Neuropathologica, 2020
- Common mechanisms in neurodegeneration and neuroinflammation: a BrainNet Europe gene expression microarray studyJournal of Neural Transmission, 2014
- Prediction of the Biological Activity Spectra of Organic Compounds Using the Pass Online Web ResourceChemistry of Heterocyclic Compounds, 2014
- Protein and ligand preparation: parameters, protocols, and influence on virtual screening enrichmentsJournal of Computer-Aided Molecular Design, 2013
- Pharmacogenetics of antidepressants and mood stabilizers2012
- Lead- and drug-like compounds: the rule-of-five revolutionDrug Discovery Today: Technologies, 2004